Combined therapy with Ukrain and chemotherapy in ovarian cancer (case report)

Drugs under Experimental and Clinical Research

Volumn 22, Issue 3-5, 1996, Pages 259-262

  Lohninger, A ^b   Korsh, O B ^a   Melnyk, A ^a  

^a Ukrainian Anti Cancer Institute   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; CYCLOPHOSPHAMIDE; UKRAIN;

ADULT; ARTICLE; CANCER STAGING; CARCINOMATOSIS; CASE REPORT; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; INTRAVENOUS DRUG ADMINISTRATION; LYMPHANGITIS; OVARY ADENOCARCINOMA; PALLIATIVE THERAPY; TUMOR RECURRENCE;

ADENOCARCINOMA; ALKALOIDS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BERBERINE ALKALOIDS; CISPLATIN; CYCLOPHOSPHAMIDE; FEMALE; HUMANS; MIDDLE AGED; OVARIAN NEOPLASMS; PHENANTHRIDINES; TOMOGRAPHY, X-RAY COMPUTED;

EID: 0029816320     PISSN: 03786501     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Blend M.J., Ostrowski G.I. Recent advances in the detection of ovarian cancer - a review. J. Am. Osteopath. Assoc., 94, 305, 1994.
2. Reed E. Promising new developments in the systemic treatment of ovarian cancer. J. Assoc. Acad. Minor. Phys., 5, 16, 1994.
3. Ozols R.F. Treatment of ovarian cancer - current status. Semin. Oncol., 21 (Suppl. 2), 1, 1994.
4. Seewaldt V.L. et al. Paclitaxel (Taxol) treatment for refractory ovarian cancer - phase II clinical trial. Am. J. Obstet. Gynecol., 170, 1666, 1994.
5. Caldas C., McGuire W.P. III Taxol in epithelial ovarian cancer. Monograph, National Cancer Institute, 15, 155, 1993.
6. Kohler D.R., Goldspiel B.R. Paclitaxel (taxol). Pharmacotherapy, 14, 3, 1994.
7. Bookman M.A., Ozols B.R. Future directions for paclitaxel (taxol) in the treatment of ovarian cancer. Semin. Oncol. Nurs., 9 (Suppl. 2), 21, 1993.
8. Rogers B.B. Taxol, a promising new drug of the 90s. Oncol. Nurs. Forum, 20, 1483, 1993.
9. Untch M. et al. Evaluation of paclitaxel (taxol), cisplatin, and the combination paclitaxel-cisplatin in ovarian cancer in vitro with ATP cell viability assay. Gynecol. Oncol., 53, 44, 1994.
10. Nowicky J.W., Nowicky W., Liepins A. Cytostatic and cytotoxic effects of Ukrain on malignant cells. VIII Mediterranean Congress of Chemotherapy, 24-29 May 1992, Athens, Greece, J. Chemother, 5, (Suppl. 1), 797, 1993.
11. Screening results-human tumour xenografts in vitro Ukrain (E90 029, W122, UKSR-22, NSC B238865). New Drug Development Office. European Organisation for Research and Treatment of Cancer.
12. Sadzuka Y. et al. Protection against cisplatin-induced nephrotoxicity in the rat by inducers and an inhibitor of glutathione S-transferase. Biochem. Pharmacol., 48, 453, 1994.
13. Verplanke A.J. et al. Comparison of renal function parameters in the assessment of cisplatin induced nephrotoxicity. Nephron, 66, 267, 1994.
14. Zhang J.G., Lindup W.E. Cisplatin nephrotoxicity - decreases in mitochondrial protein sulphydryl concentration and calcium uptake by mitochondria from rat renal cortical slices. Biochem. Pharmacol., 47, 1127, 1994.
15. Cascinu S. et al. Recombinant human erythropoietin treatment in cisplatin-associated anemia - a randomized, double-blind trial with placebo. J. Clin. Oncol., 12, 1958, 1994.
16. Okada H. et al. Granulocyte function of patients on anti-cancer chemotherapy, Nippon. Hinyoka. Gakkai. Zasshi., 85, 958, 1994.
17. Cavaletti G. et al. Long-term peripheral neurotoxicity of cisplatin in patients with successfully treated epithelial ovarian cancer. Anticancer. Res., 14 (3B), 1287, 1994.
18. Aggarwal S.K. et al. Cisplatin-induced peptic ulcers, vagotomy, adrenal and calcium modulation. Anticancer Drugs, 5, 177, 1994.
19. Blakley B.W. et al. Risk factors for ototoxicity due to cisplatin. Arch. Otolaryngol. Head Neck Surg., 120, 541, 1994.
20. Knysak D.J. et al. Immediate hypersensitivity reaction to cyclophosphamide. Arthritis. Rheum., 37, 1101, 1994.
21. De-Bandt M. et al. Treatment of acute systemic lupus erythematosus with intravenous infusions of cyclophosphamide. Value and limitations. Ann. Med. Interne (Paris), 145, 75, 1994.
22. Roberts J.C. et al. Chemoprotection against cyclophosphamide-induced urotoxicity - comparison of nine thiol protective agents. Anticancer. Res., 14 (2A), 389, 1994.
23. Roberts J.C., Francetic D.J. Chemoprotection against cyclophosphamide-induced urotoxicity - ribose-cysteine. Anticancer. Res., 14 (2A), 383, 1994.
24. Kosirog-Glowacki J.L., Bressler L.R. Cyclophosphamide -induced facial discomfort. Ann. Pharmacother., 28, 197, 1994.
25. Bokemeyer C. et al. Long-term gonadal toxicity after therapy for Hodgkin's and non-Hodgkin's lymphoma. Ann. Hematol., 68, 105, 1994.
26. Conte P.F., Role of anthracyclines in first line combination chemotherapy of ovarian carcinoma. Bull. Cancer (Paris), 80, 152, 1993.